Genetic Signatures shareholders appoint John Melki, reject three other EGM resolutions
GSS: $0.079 +5.33% · MC: $16M
Genetic Signatures shareholders appointed John Melki as a non-executive director at an extraordinary meeting, while rejecting three other resolutions. BCAL Diagnostics welcomed the appointment but reiterated its opposition to Genetic Signatures’ proposed merger with Microba, saying the terms do not adequately reflect Genetic Signatures’ contribution and calling for more information and an independent assessment for its shareholders.

Comments